☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
App
Advertisement
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Travere Therapeutics
Travere Therapeutics’ Filspari (sparsentan) Receives the US FDA’s Approval for the Reduction of Proteinuria in IgA Nephropathy
February 21, 2023
Travere Therapeutics Reports US FDA Acceptance of NDA and Priority Review for Sparsentan to Treat IgA Nephropathy
May 17, 2022
Load more...
Back to Home